Tafamidis still the only approved therapy for ATTR-CM in Asia
23 Jul 2022
byDr. Tang Hak Chiaw
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressively debilitating disease with a formidable symptom burden and an average survival of 2–5 years from diagnosis. In 2019, the US Food and Drug Administration approved tafamidis (Vyndamax) as the first disease-modifying therapy for ATTR-CM. Since then, tafamidis has been approved for the treatment of ATTR-CM in over 55 countries including Japan, Australia, and Singapore. MIMS Doctor interviewed Dr Tang Hak Chiaw, consultant cardiologist at Novena Heart Centre, Singapore, about the types and clinical presentation of ATTR-CM in Singapore, and the role of tafamidis in the treatment of this often underdiagnosed and fatal disease of the heart muscle.
